Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Loss of HER2 after neoadjuvant treatment of HER2+ early BC

Serafin Morales • 13 May 2020
ESMO Breast 2020
Breast Cancer

Serafin Morales, PhD, University Hospital Arnau de Vilanova, Lleida, Spain, discusses the loss of HER2 after neoadjuvant treatment of HER2+ early breast cancer (BC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Serafin Morales

2:29
Using genomic techniques to guide personalized medicine in breast cancer
Serafin Morales • 19 May 2020
1:01
Chemo-immunotherapy for TNBC
Serafin Morales • 12 May 2020
4:37
Latest advances in breast cancer research
Serafin Morales • 12 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals